Therapeutic Asset Ratings
271 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Pembrolizumab
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Roswell Park Cancer Institute
P2
B
(60)
Pembrolizumab
Fallopian Tube Endometrioid Adenocarcinoma
Roswell Park Cancer Institute
P2
B
(60)
Pembrolizumab
Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
Roswell Park Cancer Institute
P2
B
(60)
Fludarabine
Hepatocellular Carcinoma
Roswell Park Cancer Institute
P2
B
(59)
Binimetinib
Colorectal Carcinoma
Roswell Park Cancer Institute
P2
B
(58)
Binimetinib
Exocrine Pancreatic Carcinoma
Roswell Park Cancer Institute
P2
B
(58)
FLUTICASONE
Gliosarcoma
Roswell Park Cancer Institute
P2
B
(58)
Irinotecan
Primary Peritoneal Carcinosarcoma
Roswell Park Cancer Institute
P2
B
(58)
Nemtabrutinib
Richter Transformation
Roswell Park Cancer Institute
P2
B
(58)
Palbociclib
Colorectal Carcinoma
Roswell Park Cancer Institute
P2
B
(58)
Sargramostim
Gliosarcoma
Roswell Park Cancer Institute
P2
B
(58)
(+)-VINCRISTINE
Primary Peritoneal Carcinosarcoma
Roswell Park Cancer Institute
P2
B
(58)
Fludarabine
Chronic Leukemia
Roswell Park Cancer Institute
P2
B
(57)
CIS-DIAMMINEDICHLOROPLATINUM II
Metastatic Malignant Neoplasm in the Lung
Roswell Park Cancer Institute
P1/2
B
(57)
CIS-DIAMMINEDICHLOROPLATINUM II
Soft Tissue Sarcoma
Roswell Park Cancer Institute
P1/2
B
(57)
Decitabine
Fallopian Tube Cancer
Roswell Park Cancer Institute
P2
CCC
(55)
Dfn-15
Melanoma
Roswell Park Cancer Institute
P2
CCC
(55)
Gm-Csf
Primary Peritoneal Carcinoma
Roswell Park Cancer Institute
P2
CCC
(55)
Nemtabrutinib
Diffuse Large B-Cell Lymphoma
Roswell Park Cancer Institute
P2
CCC
(55)
Montanide Isa 51
Colorectal Cancer
Roswell Park Cancer Institute
P1/2
CCC
(55)
Rintatolimod
Breast Cancer
Roswell Park Cancer Institute
P1/2
CCC
(54)
Cetuximab Sarotalocan
Non-Small Cell Lung Carcinoma
Roswell Park Cancer Institute
P2
CCC
(53)
Cetuximab Sarotalocan
Lung Cancer
Roswell Park Cancer Institute
P2
CCC
(53)
Cyclophosphamide
Hyper-IgM Syndrome Type 1
Roswell Park Cancer Institute
P2
CCC
(53)
Cyclophosphamide
Chronic Granulomatous Disease
Roswell Park Cancer Institute
P2
CCC
(53)
Showing 76 to 100 of 271 assets
Previous
Page 4 of 11
Next